Metraipolis › archive › dc_2067604eb166

High-throughput framework for genetic analyses of adverse drug reactions using electronic health records — Europe PMC PMID:34061827

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/34061827
DOI: 10.1371/journal.pgen.1009593
License (as archived): CC0-1.0
Archived: 2026-11-04T04:40:39.505Z
SHA-256 of the archived text: d875412ab0e1f91b35ed554d4f0a7699d484becf8446c030fda632545d4f9929
Stable URL of this page: https://metraipolis.com/documento/dc_2067604eb166

How to cite

High-throughput framework for genetic analyses of adverse drug reactions using electronic health records — Europe PMC PMID:34061827 — Europe PMC (en), https://europepmc.org/article/MED/34061827 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2067604eb166 (Metraipolis archive dc_2067604eb166, sha256 d875412ab0e1f91b35ed554d4f0a7699d484becf8446c030fda632545d4f9929)

BibTeX

@misc{dc2067604eb166,
  title = {High-throughput framework for genetic analyses of adverse drug reactions using electronic health records — Europe PMC PMID:34061827},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34061827},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2067604eb166; sha256 d875412ab0e1f91b35ed554d4f0a7699d484becf8446c030fda632545d4f9929},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34061827. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Understanding the contribution of genetic variation to drug response can improve the delivery of precision medicine. However, genome-wide association studies (GWAS) for drug response are uncommon and are often hindered by small sample sizes. We present a high-throughput framework to efficiently identify eligible patients for genetic studies of adverse drug reactions (ADRs) using "drug allergy" labels from electronic health records (EHRs). As a proof-of-concept, we conducted GWAS for ADRs to 14 common drug/drug groups with 81,739 individuals from Vanderbilt University Medical Center's BioVU DNA Biobank. We identified 7 genetic loci associated with ADRs at P < 5 × 10-8, including known genetic associations such as CYP2D6 and OPRM1 for CYP2D6-metabolized opioid ADR. Additional expression quantitative trait loci and phenome-wide association analyses added evidence to the observed associations. Our high-throughput framework is both scalable and portable, enabling impactful pharmacogenomic research to improve precision medicine.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS genetics, 2021 (prima pubblicazione 2021-06-01).
Identificativi: PMID 34061827 · PMCID PMC8195357 · DOI 10.1371/journal.pgen.1009593.
Descrittori MeSH principali: Electronic Health Records.
Pagina: https://europepmc.org/article/MED/34061827 — https://doi.org/10.1371/journal.pgen.1009593. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-04T04:32:54.764Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.